{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72","upperLimit":"233","value":"134"},{"groupId":"OG001","lowerLimit":"225","upperLimit":"225","value":"225"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"DOR was defined as time from date of first documentation of a PR or better to date of first documentation of progressive disease (PD) for responders. Increase of \\>25% from lowest response value in any one or more of following: Serum M-component and/or (absolute increase must be \\>0.5 g/dL); Urine M-component and/or (the absolute increase must be \\>200 mg/24 h); difference between involved and uninvolved free light chain (FLC) levels and the absolute increase must be \\> 10 mg/dL; Bone marrow plasma cell percentage; absolute percentage must be \\> 5%; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcaemia (corrected serum calcium \\> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Responders without PD were censored at the date of the last response assessment that was stable disease (SD) or better.","dispersionType":"Full Range","groups":[{"description":"After part A the participant has the option to participate in Part B start with ixazomib capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Normal Renal Function: Ixazomib"},{"description":"After part A the participant has the option to participate in Part B start with ixazomib capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Severe Renal Impairment: Ixazomib"},{"description":"After part A the participant has the option to participate in Part B start with ixazomib capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG002","title":"End-stage Renal Disease: Ixazomib"}],"paramType":"MEDIAN","populationDescription":"Response evaluable population is defined as participants who received at least 1 cycle of Ixazomib treatment in Part B and at least 1 post-baseline response assessment. Here, number of participants analyzed is the participants who had confirmed response.","reportingStatus":"POSTED","timeFrame":"Day 1 of every other cycle from cycle 1 (each cycle of 28 days) up to progression of disease (approximately up to 855 days)","title":"Duration of Response (DOR) in RRMM Participants","type":"SECONDARY","unitOfMeasure":"days"}